---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-081799"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:56:15.310819+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics posts updated presentation detailing Phase 3 plans for tecarfarin in LVAD and other indications

## Summary
- Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.
- Tecarfarin has FDA Orphan Drug Designation for LVAD and ESKD+AFib, and Fast Track for ESKD+AFib.
- Cash $5.0M, no debt, market cap $14.2M as of 9/18/24; insider ownership 42%.
- Phase 2/3 data showed tecarfarin achieved higher TTR (70% vs 67%, p=0.04) and fewer thrombotic events than warfarin.
- Presentation also outlines targeted indications: MHV patients with difficult-to-control TTR or warfarin resistance.

## SEC filing metadata
- accession: 0001213900-24-081799
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/0001213900-24-081799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/ea0215596-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-081799
- JSON: https://secwatch.observer/filing/0001213900-24-081799.json
- Plain text: https://secwatch.observer/filing/0001213900-24-081799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.